BeyondSpring Inc, a global biopharmaceutical company, is developing plinabulin, a selective immunomodulating microtubule-binding agent, as a potential anti-cancer drug and for preventing chemotherapy-induced neutropenia (CIN). Plinabulin has shown promising results in extending overall survival in non-small cell lung cancer and has received Breakthrough status for CIN prevention. BeyondSpring is also exploring plinabulin's potential in combination regimens with radiation and checkpoint inhibitors for various cancers. Additionally, the company has three preclinical immuno-oncology assets and majority ownership in SEED Therapeutics, a subsidiary focused on targeted protein degradation drug discovery.